Radequinil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Radequinil
Radequinil.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C18H14N4O3
Molar mass 334.329 g/mol
3D model (Jmol)

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

See also[edit]

References[edit]

  1. ^ a b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23. 
  2. ^ Pogacic, Vanda; Herling, Paul (2007). "List of Drugs in Development for Neurodegenerative Diseases". Neurodegenerative Diseases. 4 (6): 443486. doi:10.1159/000107705. ISSN 1660-2862.